12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196 | Completed Phase 3 Results

• 2 other identifiers: NAK-062013-000894-56
• Study Type: interventional
• Target: 535
• Locations: 11 countries
• Sites: 127

Brief Summary

Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial aims at the evaluation of the efficacy and safety of oral ibodutant 10 mg once daily as compared to placebo in women with IBS-D over a 12-week treatment period.

Conditions

Irritable Bowel Syndrome With Diarrhea

Keywords

Irritable Bowel Syndrome; Colon, irritable; Bowel disease; Diarrhea

Outcome Measures

Primary Outcomes (1)

• Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).

  The patient will be considered a weekly responder if she meets both of the following criteria in the same week: * Abdominal pain response: decrease in weekly average of worst abdominal pain score in the past 24 hours of at least 30% compared with baseline; * Stool consistency response: decrease of at least 50% in the number of days per week with at least one stool that has a consistency of Type 6 or 7 compared with baseline. The patients reported Bristol Stoll Chart score based on a 1 to 7 scale where 1 corresponds to hard stool and 7 corresponds to watery diarrhoea.

  12 weeks

Secondary Outcomes (4)

• Weekly Response for Abdominal Pain Intensity Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).

  12 weeks

• Weekly Response for Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).

  12 weeks

• Weekly Response for Relief of Overall IBS Signs and Symptoms Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks).

  12 weeks

• Evaluation of Rebound Effects

  4 weeks

Study Arms (2)

Ibodutant 10 mg

EXPERIMENTAL

Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the ibodutant 10 mg arm will be re-randomised at week 13 in a 1:1 ratio to either ibodutant 10 mg or placebo for additional 4 weeks of treatment.

Drug: Ibodutant 10 mg

Placebo

PLACEBO COMPARATOR

Oral tablet to be given once daily for 12 weeks of treatment. Patients randomised to the placebo arm will be mock-re-randomised (switch in blinded conditions) to ibodutant at week 13 for additional 4 weeks of treatment.

Drug: Placebo

Interventions

Ibodutant 10 mg DRUG

Oral tablet, to be given once daily.

Also known as: Code: MEN 15596

Ibodutant 10 mg

Placebo DRUG

Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.

Also known as: Sugar pill

Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At screening:
• Female patients aged 18 years or older.
• Clinical diagnosis of IBS-D according to the following symptoms-based criteria as per Rome III modular questionnaire criteria:
• Recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months associated with at least 2 of the following characteristics: a) improvement with defecation; b) onset associated with a change in the frequency of stool; c) onset associated with a change in form (appearance) of stool.
• Symptom-onset at least 6 months prior to diagnosis.
• Loose or watery stools at least 25% of the time in the last 3 months AND hard or lumpy stools less than 25% of the time in the last 3 months.
• Additional criterion: more than 3 bowel movements per day at least 25% of the time in the last 3 months.
• For patients older than 50 years OR patients with a positive family history of colorectal cancer: normal results from colonoscopy/flexible sigmoidoscopy performed within the last 5 years.
• For patients aged 65 years or older: absence of ischaemic colitis, microscopy colitis or any other organic gastrointestinal disease as evidenced by the results of a colonoscopy/flexible sigmoidoscopy with biopsy performed within 6 months.
• For women of childbearing potential: Use of a highly effective contraceptive method with a failure rate \<1% per year throughout the entire study period.
• Physical examination without clinically relevant abnormalities during screening.
• No clinically relevant abnormalities in 12-Lead ECG or in laboratory findings.
• Mentally competent, able to give written informed consent, and compliant to undergo all visits and procedures.
• Unrestricted access to a touch-tone telephone.
• Willingness to refrain from using loperamide within 3 days prior to run-in visit and during the run-in period.

You may not qualify if:

• Male gender.
• Diagnosis of IBS with a subtype of constipation, mixed IBS, or un-subtyped IBS.
• Colonic or major abdominal surgery, any other major abdominal surgery or elective major surgery planned or expected during the study.
• History of organic GI abnormalities, inflammatory bowel diseases, complicated diverticulosis, ischaemic colitis, microscopic colitis.
• History of pancreatitis, active biliary duct disease, cholecystitis or symptomatic gallbladder stone disease in the previous 6 months.
• History of gluten enteropathy or lactose intolerance.
• Current or previous diagnosis of neoplasia.
• History of endometriosis.
• History of positive tests for ova or parasites, or clostridium difficile toxin or occult blood in the stool in the previous 6 months.
• History of human immunodeficiency virus infection.
• History of major cardiovascular events in the previous 6 months.
• Uncontrolled hypertension, insulin-dependent diabetes mellitus or abnormal thyroid function.
• Major psychiatric or neurological disorders or unstable medical condition which may compromise the efficacy and safety assessments.
• Evidence of clinically significant hepatic disease, severe renal insufficiency or anemia.
• Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2 months.

Sponsors & Collaborators

• Menarini Group: lead

Study Sites (127)

Unknown Facility

Huntsville, Alabama, 35802, United States

Location

Unknown Facility

Sherwood, Arizona, 72120, United States

Location

Unknown Facility

Little Rock, Arkansas, 72205, United States

Location

Unknown Facility

Artesia, California, 90701, United States

Location

Unknown Facility

Chula Vista, California, 91910, United States

Location

Unknown Facility

Encino, California, 91436, United States

Location

Unknown Facility

Mission Hills, California, 91345, United States

Location

Unknown Facility

Sacramento, California, 95821, United States

Location

Unknown Facility

San Diego, California, 92123, United States

Location

Unknown Facility

Upland, California, 91786, United States

Location

Unknown Facility

Littleton, Colorado, 80127, United States

Location

Unknown Facility

Bristol, Connecticut, 06010, United States

Location

Unknown Facility

Boynton Beach, Florida, 33426, United States

Location

Unknown Facility

Brandon, Florida, 33511, United States

Location

Unknown Facility

Brooksville, Florida, 34601, United States

Location

Unknown Facility

Coral Gables, Florida, 33134, United States

Location

Unknown Facility

Gainesville, Florida, 32607, United States

Location

Unknown Facility

Hialeah, Florida, 33012, United States

Location

Unknown Facility

Jupiter, Florida, 33458, United States

Location

Unknown Facility

Miami, Florida, 33125, United States

Location

Unknown Facility

Miami, Florida, 33165, United States

Location

Unknown Facility

Miami, Florida, 33175, United States

Location

Unknown Facility

Miami, Florida, 33185, United States

Location

Unknown Facility

Miami Lakes, Florida, 33014, United States

Location

Unknown Facility

Addison, Illinois, 60101, United States

Location

Unknown Facility

Chicago, Illinois, 60604, United States

Location

Unknown Facility

Augusta, Kansas, 67010, United States

Location

Unknown Facility

Newton, Kansas, 67114, United States

Location

Unknown Facility

Wichita, Kansas, 67205, United States

Location

Unknown Facility

Lexington, Kentucky, 40509, United States

Location

Unknown Facility

Madisonville, Kentucky, 42431, United States

Location

Unknown Facility

Owensboro, Kentucky, 42303, United States

Location

Unknown Facility

Crowley, Louisiana, 70526, United States

Location

Unknown Facility

Baltimore, Maryland, 21215, United States

Location

Unknown Facility

Ann Arbor, Michigan, 48106, United States

Location

Unknown Facility

Chesterfield, Michigan, 48047, United States

Location

Unknown Facility

Saginaw, Michigan, 48604, United States

Location

Unknown Facility

Troy, Michigan, 48098, United States

Location

Unknown Facility

Las Vegas, Nevada, 89128, United States

Location

Unknown Facility

Hartsdale, New York, 10530, United States

Location

Unknown Facility

Fayetteville, North Carolina, 28304, United States

Location

Unknown Facility

Greensboro, North Carolina, 27408, United States

Location

Unknown Facility

Fargo, North Dakota, 58103, United States

Location

Unknown Facility

Akron, Ohio, 44302, United States

Location

Unknown Facility

Cincinnati, Ohio, 45219, United States

Location

Unknown Facility

Cincinnati, Ohio, 45242, United States

Location

Unknown Facility

Cleveland, Ohio, 44122, United States

Location

Unknown Facility

Columbus, Ohio, 43214, United States

Location

Unknown Facility

Dayton, Ohio, 45432, United States

Location

Unknown Facility

Reading, Pennsylvania, 19606, United States

Location

Unknown Facility

Greer, South Carolina, 29650, United States

Location

Unknown Facility

Simpsonville, South Carolina, 29681, United States

Location

Unknown Facility

Chattanooga, Tennessee, 37421, United States

Location

Unknown Facility

Knoxville, Tennessee, 37912, United States

Location

Unknown Facility

Knoxville, Tennessee, 37919, United States

Location

Unknown Facility

Nashville, Tennessee, 37205, United States

Location

Unknown Facility

Smyrna, Tennessee, 37167, United States

Location

Unknown Facility

Beaumont, Texas, 77701, United States

Location

Unknown Facility

Houston, Texas, 77052, United States

Location

Unknown Facility

Houston, Texas, 77089, United States

Location

Unknown Facility

Hurst, Texas, 76054, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Ste. Channelview, Texas, 77530, United States

Location

Unknown Facility

West Jordan, Utah, 84088, United States

Location

Unknown Facility

Morgantown, West Virginia, 26505, United States

Location

Unknown Facility

Haskovo, 6300, Bulgaria

Location

Unknown Facility

Plovdiv, 4002, Bulgaria

Location

Unknown Facility

Rousse, 7002, Bulgaria

Location

Unknown Facility

Sofia, 1407, Bulgaria

Location

Unknown Facility

Sofia, 1431, Bulgaria

Location

Unknown Facility

Veliko Tarnovo, 5000, Bulgaria

Location

Unknown Facility

Karlovy Vary, 360 66, Czechia

Location

Unknown Facility

Prague, 14021, Czechia

Location

Unknown Facility

Prague, 19000, Czechia

Location

Unknown Facility

Ústí nad Labem, 401 13, Czechia

Location

Unknown Facility

Ústí nad Orlicí, 562 01, Czechia

Location

Unknown Facility

Bordeaux, 33000, France

Location

Unknown Facility

Nantes, 44093, France

Location

Unknown Facility

Nice, 06202, France

Location

Unknown Facility

Rouen, 76031, France

Location

Unknown Facility

Bobigny, Île-de-France Region, 93000, France

Location

Unknown Facility

Stuttgart, Baden-Wurttemberg, 70593, Germany

Location

Unknown Facility

Berlin, 10629, Germany

Location

Unknown Facility

Berlin, 13125, Germany

Location

Unknown Facility

Essen, 45355, Germany

Location

Unknown Facility

Hamburg, 20253, Germany

Location

Unknown Facility

Hamburg, 22297, Germany

Location

Unknown Facility

Bari, 70100, Italy

Location

Unknown Facility

Bari, 70124, Italy

Location

Unknown Facility

Bologna, 40138, Italy

Location

Unknown Facility

Florence, 50139, Italy

Location

Unknown Facility

Pavia, 27100, Italy

Location

Unknown Facility

Rome, 00168, Italy

Location

Unknown Facility

Bydgoszcz, 85-168, Poland

Location

Unknown Facility

Częstochowa, 42-200, Poland

Location

Unknown Facility

Krakow, 31009, Poland

Location

Unknown Facility

Lublin, 20-090, Poland

Location

Unknown Facility

Wroclaw, 53333, Poland

Location

Unknown Facility

Târgu Mureş, Jud. Mures, 540461, Romania

Location

Unknown Facility

Târgu Mureş, Mureș County, 540098, Romania

Location

Unknown Facility

Timișoara, Timiș County, 300168, Romania

Location

Unknown Facility

Timișoara, Timiș County, 300193, Romania

Location

Unknown Facility

Brasov, 500283, Romania

Location

Unknown Facility

Brasov, 500326, Romania

Location

Unknown Facility

Bucharest, 20125, Romania

Location

Unknown Facility

Bucharest, 50098, Romania

Location

Unknown Facility

Kaluga, 248007, Russia

Location

Unknown Facility

Moscow, 115446, Russia

Location

Unknown Facility

Saint Petersburg, 193015, Russia

Location

Unknown Facility

Saint Petersburg, 194295, Russia

Location

Unknown Facility

Saint Petersburg, 196247, Russia

Location

Unknown Facility

Smolensk, 214019, Russia

Location

Unknown Facility

Yaroslavl, 150000, Russia

Location

Unknown Facility

Badalona, Barcelona, 08916, Spain

Location

Unknown Facility

Mataró, Barcelona, 8304, Spain

Location

Unknown Facility

Sabadell, Barcelona, 08208, Spain

Location

Unknown Facility

Barcelona, 08022, Spain

Location

Unknown Facility

Barcelona, 08035, Spain

Location

Unknown Facility

Madrid, 28040, Spain

Location

Unknown Facility

Seville, 41013, Spain

Location

Unknown Facility

Penzance, Cornwall, TR18 4JH, United Kingdom

Location

Unknown Facility

Chesterfield, Derbyshire, S40 4AA, United Kingdom

Location

Unknown Facility

Inverness, Scotland, IV2 4AG, United Kingdom

Location

Unknown Facility

Doncaster, South Yorkshire, DN2 5LT, United Kingdom

Location

Unknown Facility

Leicestershire, LE10 2SE, United Kingdom

Location

Unknown Facility

Manchester, M23 9LT, United Kingdom

Location

Unknown Facility

Plymouth, Devon, PL5 3JB, United Kingdom

Location

MeSH Terms

Conditions

Irritable Bowel Syndrome; Intestinal Diseases; Diarrhea

Interventions

ibodutant; Sugars

Condition Hierarchy (Ancestors)

Colonic Diseases, Functional; Colonic Diseases; Gastrointestinal Diseases; Digestive System Diseases; Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Carbohydrates

Results Point of Contact

• Title: Angela Capriati, MD PhD - Corporate Director Clinical Research
• Organization: MENARINI Group

acapriati@menarini-ricerche.it

+39 055 5680

Study Officials

• Jan F Tack, Professor

  Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  STUDY CHAIR

• Lin Chang, Professor

  Digestive Health and Nutrition Clinic. University of California, Los Angeles, CA, USA

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2014
• First Posted: April 8, 2014
• Study Start: March 1, 2014
• Primary Completion: June 1, 2015
• Study Completion: June 1, 2015
• Last Updated: January 19, 2017
• Results First Posted: September 27, 2016

Record last verified: 2016-11

Locations

ES (7); FR (5); DE (6); US (65); IT (6); RO (8); GB (7); PL (5); BU (6); RU (7); CZ (5)